Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-01-01
2008-01-01
Anderson, Rebecca (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S235000, C548S236000
Reexamination Certificate
active
07314884
ABSTRACT:
The present invention relates to compounds of formula (I)wherein R1, R2, and X are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.
REFERENCES:
patent: 5455351 (1995-10-01), Kempf et al.
patent: 6011155 (2000-01-01), Villhauer
patent: 6110949 (2000-08-01), Villhauer
patent: 6124305 (2000-09-01), Villhauer
patent: 6861440 (2005-03-01), Boehringer et al.
patent: 19616486 (1997-10-01), None
patent: 19616486 (1997-10-01), None
patent: 19834591 (2000-02-01), None
patent: WO 95/01976 (1995-01-01), None
patent: WO 96/10018 (1996-04-01), None
patent: WO 98/19998 (1998-05-01), None
patent: WO 99/38501 (1999-08-01), None
patent: WO 99/38501 (1999-08-01), None
patent: WO 00/08002 (2000-02-01), None
patent: WO 00/34241 (2000-06-01), None
patent: WO 01/19805 (2001-03-01), None
patent: WO 01/34594 (2001-05-01), None
patent: WO 01/40180 (2001-06-01), None
patent: WO 01/55105 (2001-08-01), None
patent: WO 01/62266 (2001-08-01), None
patent: WO 02/30890 (2002-04-01), None
NOVARTIS AG, Expert Opinion on Therapeutic Patents, Ashley Publications, GB, vol. 10, No. 12, pp. 1937-1942 (2000).
Schunack et al., Z. Naturforschung, 42b, pp. 238-242 (1987).
Lipp et al., Eur. J. Med. Chem., 30, pp. 219-225 (1995).
Horne et al., Heterocycles, 39, pp. 139-153, (1994).
Francis et al., Tetrahedron Letters, 28, pp. 5133-5136 (1987).
Ali et al., Pak. J. Sci. Ind. Res., 36, pp. 502-510 (1993).
Weintraub, P.M., J. Med. Chem, 15, pp. 419-420 (1972).
Goto et al., Chem. Pharm. Bull., 19, pp. 2050-2057 (1971).
Golfier et al., J. Heterocycl. Chem., 10, pp. 989-991 (1973).
Singh et al., Ind. J. Chem., 22B, pp. 1177-1178 (1983).
Carrera et al., Synlett, 1, p. 93-94 (1994).
Agarwal et al., Synth. Commun., 23, pp. 1101-1110 (1993).
Qizhuang et al., J. Med. Chem., 32, pp. 478-486 (1989).
Freedman et al., J. Heterocycl. Chem., 27, pp. 343-346 (1990).
Collins et al., J. Med. Chem., 41, pp. 5037-5054 (1998).
Boehringer Markus
Hunziker Daniel
Kuehne Holger
Loeffler Bernd Michael
Sarabu Ramakanth
Anderson Rebecca
Hoffmann-La Roche Inc.
Johnston George W.
Megerditchian Samuel H.
Tramaloni Dennis P.
LandOfFree
DPP IV inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with DPP IV inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and DPP IV inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2754303